Ultragenyx Pharmaceutical (RARE) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Ultragenyx Pharmaceutical published the results on November 3, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• Ultragenyx's release reports figures in whole millions, which is how they appear here. It reports one EPS figure, net loss per share on a GAAP basis, with no adjusted measure.
• Ultragenyx has sold a percentage of its future CRYSVITA royalty payments from the U.S. and Canada, subject to caps, to OMERS and Royalty Pharma. It still records those royalties as revenue, and records non-cash interest expense on the liability for sales of future royalties.

Source: Ultragenyx Q3 2026 results, November 3, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Ultragenyx Pharmaceutical splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Ultragenyx Pharmaceutical's Total CRYSVITA Revenue revenue was $109 million in Q3 2026, down 3% from $112 million in Q3 2025, 63% of total revenue.
• Ultragenyx Pharmaceutical's DOJOLVI revenue was $30.0 million in Q3 2026, up 25% from $24.0 million in Q3 2025, 17% of total revenue.
• Ultragenyx Pharmaceutical's EVKEEZA revenue was $24.0 million in Q3 2026, up 41% from $17.0 million in Q3 2025, 14% of total revenue.
• Ultragenyx Pharmaceutical's MEPSEVII revenue was $10.0 million in Q3 2026, up 43% from $7.0 million in Q3 2025, 6% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Ultragenyx Pharmaceutical said:

“The company reaffirms its full year 2026 total revenue guidance of $730 million to $760 million, which excludes revenue from new product launches.”

“The company reaffirms its full year 2026 Crysvita revenue guidance of $500 million to $520 million.”

“The company reaffirms its full year 2026 Dojolvi revenue guidance of $100 million to $110 million.”

“The company continues to anticipate achieving full-year GAAP profitability in 2027 and going forward.”

Source: Ultragenyx Q3 2026 release, Nov 3, 2026.

This is the company's own guidance as of Nov 3, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the RARE forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP total revenues and net loss per share, each as first reported in that quarter's release. Releases from Q4 2025 on print revenue in whole millions; the Q3 2025 release printed it in thousands.

We do not hold a confirmed date for Ultragenyx Pharmaceutical's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 3, 2026

Ultragenyx Pharmaceutical's total revenues were $173 million in Q3 2026, against $160 million. CRYSVITA brought in $109 million, against $112 million, followed by DOJOLVI at $30 million, EVKEEZA at $24 million and MEPSEVII at $10 million. The 10-Q puts the rise down mainly to demand for approved products and the timing of shipments. (Ultragenyx Q3 2026 release, Nov 3, 2026; Ultragenyx Form 10-Q, Q3 2026, Nov 4, 2026)

CRYSVITA revenue comes in three forms. Ultragenyx books product sales in Latin America and Türkiye ($41 million, down from $47 million), and receives royalty revenue from Kyowa Kirin on sales in the U.S. and Canada ($61 million) and Europe ($7 million). Kyowa Kirin took over commercialization in the U.S. and Canada in April 2023, after which Ultragenyx receives a revenue share intended to approximate the old profit-share. (Ultragenyx Q3 2026 release, Nov 3, 2026; Ultragenyx Form 10-K, 2025, Feb 18, 2026)

Ultragenyx has sold rights to part of those CRYSVITA royalties to Royalty Pharma and OMERS. It still records the royalties as revenue, and the liability for sales of future royalties stood at $1,186 million at September 30, 2026, generating $20 million of non-cash interest expense in the quarter. (Ultragenyx Form 10-Q, Q3 2026, Nov 4, 2026; Ultragenyx Q3 2026 release, Nov 3, 2026)

By geography, North America accounted for $90 million of Q3 2026 revenue, Latin America $39 million, Europe, Middle East, and Africa $37 million and Asia-Pacific $7 million. Product sales were $105 million and royalty revenue $68 million. (Ultragenyx Form 10-Q, Q3 2026, Nov 4, 2026)

Ultragenyx Pharmaceutical's net loss narrowed to $118 million, or $1.16 per share, in Q3 2026 from $180 million, or $1.81. Research and development expense fell to $154 million from $216 million, while selling, general and administrative rose to $97 million from $87 million. Total operating expenses of $283 million included $34 million of non-cash stock-based compensation. (Ultragenyx Q3 2026 release, Nov 3, 2026)

Before FDA approval of GENGLYCOS in August 2026 and FAYUVI in September 2026, Ultragenyx expensed their manufacturing costs as research and development, so that earlier inventory carries no cost of sales. Ultragenyx expects cost of sales to rise relative to product revenue as it uses up that previously expensed inventory. (Ultragenyx Form 10-Q, Q3 2026, Nov 4, 2026)

Weighted shares rose to 102.1 million from 99.8 million. The quarter also had a $9 million tax benefit. In October 2026 Ultragenyx agreed to sell the two Priority Review Vouchers it received with the approvals for a combined $413 million, with net proceeds expected to be about $350 million. (Ultragenyx Q3 2026 release, Nov 3, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Ultragenyx Pharmaceutical gives revenue guidance in its release. It reaffirmed full year 2026 total revenue of $730 million to $760 million, which excludes revenue from the new GENGLYCOS and FAYUVI launches, CRYSVITA revenue of $500 million to $520 million and DOJOLVI revenue of $100 million to $110 million. (Ultragenyx Q3 2026 release, Nov 3, 2026)

Ultragenyx also said it expects full-year GAAP profitability in 2027. It is cutting headcount by about 20%, to about 1,000 employees, and expects 2027 R&D expenses below $350 million and SG&A below $375 million, with about $25 million of severance and restructuring charges in Q4 2026. (Ultragenyx Q3 2026 release, Nov 3, 2026)

A consensus figure is the average of the models published by the analysts who cover Ultragenyx Pharmaceutical, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Ultragenyx Pharmaceutical's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning RARE is on is RARE a buy or a sell?, what analysts expect next is on the RARE forecast, and what the company does is on the Ultragenyx Pharmaceutical (RARE) stock page.

Every number on this page can be traced to a document Ultragenyx Pharmaceutical published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.